Biotechnology Press Release
|05/14/2020 - 01:24||
Ritter Pharmaceuticals, Inc. Announces Adjournment of its Special Meeting
The special meeting was adjourned to allow the Company additional time to solicit proxies in favor of the proposals to be acted on by stockholders at the meeting.
|05/14/2020 - 01:21||
MEI Pharma and Kyowa Kirin Announces ME-401 Phase 1b Study to be Highlighted in a Presentation at the Virtual Edition of the 25th European Hematology Association Annual Congress
Title: The PI3kδ Inhibitor ME-401 is Well-Tolerated on Intermittent Schedule and Produces a High-Rate of Durable Responses in Relapsed Refractory (R/R) Indolent B-Cell Malignancies Session Title: Indolent and mantle-cell non-Hodgkin lymphoma - Clinical Authors: John Pagel, et.
|05/14/2020 - 01:15||
ASTA Statement on USDAs Secure Rule
Alexandria, VA—May 14, 2020–The American Seed Trade Association (ASTA) greatly appreciates the efforts of Secretary Perdue and his team in working to provide clarity around USDA’s regulatory system for genetically engineered organisms – through the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) rule. Plant breeding innovations like gene editing hold tremendous potential not just for American agriculture, but for the future of our environment and the entire food value chain. Innovation is the backbone of America.
|American Seed T...|
|05/14/2020 - 00:44||
Halozyme To Receive $15 Million Milestone Payment From Janssen
The milestone payment is associated with the first commercial sale in the United States of Janssen's DARZALEX FASPROTM (daratumumab and hyaluronidase - fihj) utilizing ENHANZE®, which was recently approved by the U.S. Food and Drug Administration.
|05/13/2020 - 17:05||
Eight high school seniors awarded $1,000 YF&R scholarship
The Oklahoma Farm Bureau Young Farmers and Ranchers committee has awarded eight high school seniors with a $1,000 college scholarship.
|Oklahoma Farm Bureau|
|05/13/2020 - 16:33||
Cloth masks are a worthy line of defense to mitigate COVID-19 pandemic
Tiny particles are subject to Brownian motion, where they dart about randomly.This allows cloth masks to have more efficiency than expected.
|05/13/2020 - 09:45||
American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host Disease.
|05/13/2020 - 04:04||
Campus volunteers support Covid-19 research
Staff volunteers provide essential administrative support to research involving all UK coronavirus patients in intensive care.
|05/13/2020 - 03:30||
Genetics of Covid-19 patients is focus of study
A UK-wide initiative will sequence the genetic makeup – the whole genome – of patients to identify the specific genes that cause a predisposition to the disease.
|05/13/2020 - 02:37||
U of T researchers aim to make testing for COVID-19 'simpler and more streamlined'
Leo Chou, of the Institute of Biomaterials and Biomedical Engineering, says his non-traditional approach to testing for the novel coronavirus could help avoid the bottlenecks that have emerged with established methods (photo by Qin Dai)
|05/13/2020 - 00:26||
Readout from Chairman Reeds Meeting with U.S. Ambassador to the African Union Jessica Lapenn
WASHINGTON – President and Chairman of the Export-Import Bank of the United States (EXIM) Kimberly A. Reed met today via teleconference with U.S. Ambassador to the African Union Jessica Lapenn (link is external) to address how EXIM can help American businesses export their “Made in the U.S.A.” goods and services to the African continent.
|05/12/2020 - 21:02||
New partnership to sequence human genomes in the fight against coronavirus
Genetic susceptibility to coronavirus to be tested in ground-breaking nationwide study Genomes of thousands of patients with coronavirus will be sequenced to understand how a person’s genetic makeup could influence how they react to the virus Genomics England partners with University of Edinburgh to lead research drive to support the search for new treatments.
|05/12/2020 - 20:47||
Digging Deeper: COVID-19 Answers at the Cellular Level
What makes some COVID-19 cases worse than others? That’s the question confronting medical teams as they make momentous decisions for the care of their patients. While risk factors like age and pre-existing health conditions play a role in outcomes, there are factors yet undiscovered that could lead to improved therapies, better health care, and an effective vaccine. To find them, Nadia Roan, PhD, a scientist at Gladstone and UC San Francisco (UCSF), along with UCSF scientists Sulggi Lee, MD, PhD, and Joshua Vasquez, MD, are looking into patients’ blood and tissues.
|05/12/2020 - 20:24||
Virtual hackathon unites international community to tackle Covid-19
University students and professionals connect online to find practical solutions to problems linked with the current pandemic.
|05/12/2020 - 20:15||
Learn more about Gladstone's COVID-19 research projects and how science will overcome this pandemic.
In response to the COVID-19 pandemic, Gladstone scientists have rapidly pivoted the focus of their research labs to the novel virus, SARS-CoV-2.
|05/12/2020 - 19:56||
SMART researchers uncover new anti-phage defense mechanisms
Discovery explains why some bacteria have been able to defend against phage therapy, opens new ways to overcome existing challenges.
|05/12/2020 - 16:05||
FDA Further Expands EUA for Thermo Fisher Scientific's COVID-19 Diagnostic Tests
Authorization brings more instruments on line, enables workflow flexibility and simplifies methods to increase throughput and allow more labs to run tests.
|Thermo Fisher S...|
|05/12/2020 - 16:00||
Mice with patchy coats lay bare how stem cells endure
Mice deficient in NFIB and NFIX have degenerated follicles (green ovals) and an unusually thick skin (red).
|05/12/2020 - 15:26||
THE ROHATYN GROUP COMPLETES INVESTMENT IN EUROPEAN CONTRACT RESEARCH ORGANIZATION, OPTIMAPHARM
New York, NY, May 12, 2020 – The Rohatyn Group (“TRG”), an emerging markets focused asset management firm, today announced that it has completed an investment in Optimapharm d.d. (“Optimapharm” or the “Company”), to establish a partnership with the company’s founders Gordana Gregurić Čičak and Igor Čičak. Optimapharm is a contract research organization (“CRO”) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.
|The Rohatyn Group|
|05/12/2020 - 13:22||
Made-in-Canada solution needed to ensure masks and other essential medical supplies there for next pandemic, says CCPA
VANCOUVER - Canada should aim to become completely self-sufficient in producing masks and other essential medical supplies needed during pandemics and rely on the country’s forest industry—not its oil industry—to get the job done, says the BC office of the Canadian Centre for Policy Alternatives.
|05/12/2020 - 10:29||
Agilent Awards Trilogy Sciences with a Golden Ticket at LabCentral
Agilent Technologies Inc. (NYSE: A) announces that biotech startup Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge, Massachusetts. LabCentral is a shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups. The Golden Ticket provides funding of one lab bench space for a year.
|05/12/2020 - 09:02||
Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020 at 9:45 a.m.
|05/12/2020 - 00:01||
Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19
Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19https://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttps://www.nascentbiotech.com/wp-content/uploads/2017/09/nascent-articles.jpg
|05/11/2020 - 21:37||
Commuting to the Lab during a Pandemic: Meet the Scientists Who Are Studying COVID-19
These are just some of the Gladstone scientists who have volunteered to go to the lab to study coronavirus.
|05/11/2020 - 19:38||
Slater Technology Fund Invests in Pharmaceutical Startup Developing Novel Cancer Therapeutics
URI-based Company is Developing Promising New Synthetic Molecules for Use in Treating Ovarian Cancer.